🔎 Trials Near Me

Beranda › Limfoma Folikuler › Texas

Uji klinis Limfoma Folikuler di Texas

35 studi untuk Limfoma Folikuler mencari peserta di lokasi di Texas.

Kota di Texas

Teks studi resmi (Bahasa Inggris)

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

  • NEXT Dallas, Irving
  • NEXT Oncology, San Antonio
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT03460977

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Texas Children's Hospital, Houston
Menerima pesertaStudi observasional
Usia 0 hingga 38 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06131801

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

  • Research Site, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06542250

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Md Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Texas Oncology - DFW (Sammons CC), Dallas
  • Baylor College of Medicine, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07226843

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • University of Texas Southwestern, Dallas
  • MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07101328

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

  • Baylor Scott & White Research Institute, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
  • South Texas Accelerated Research Therapeutics (START), San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05765812

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

  • Research Site, Austin
  • Research Site, Lubbock
  • Research Site, Shenandoah
  • dan 1 lainnya
Menerima pesertaFase 3
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06549595

NEO100 and High-Grade Meningioma

  • Baylor Scott and White, Dallas
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT05023018

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  • Research Site, Austin
  • Research Site, Houston
  • Research Site, San Antonio
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06526793

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  • Texas Oncology, Dallas
Menerima pesertaFase 3
Usia 12 hingga 100 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06784752

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  • Center for Oncology and Blood Disorders, Houston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06091254

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

  • MD Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06043323

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

  • Research Site, San Antonio
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT07546760

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

  • M D Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT06108232

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • University of Texas Southwestern Medical Center, Dallas
  • MD Anderson Cancer Center, Houston
  • University of Texas Health Mays Cancer Center, San Antonio
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT05303519

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • Baylor University Medical Center, Dallas
  • Texas Transplant Institute, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05826535

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • University of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 13 hingga 90 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06533579

Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)

  • Natera, Inc., Austin
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07750886

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

  • The University of TX MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT07424833

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

  • Memorial Hermann Hospital / UTHealth McGovern Medical School at Houston, Houston
  • The University of Texas Health Science at San Antonio, San Antonio
Menerima pesertaFase 2
Usia 18 hingga 55 · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT05951777

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT05131022

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

  • Texas Liver Institute - American Research Corporation, San Antonio
  • Pinnacle Clinical Research, San Antonio
Menerima pesertaFase 1
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 16 Jun 2026 · NCT07559474

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

  • Texas Oncology - Central/South Texas, Austin
  • Local Institution - 0212, Fort Worth
  • Local Institution - 0230, San Antonio
  • dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Mei 2026 · NCT06911502

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • University of Texas(UT) Southwestern-Children's Medical Center, Dallas
Menerima pesertaFase 1/2
Usia 12 hingga 95 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Mar 2026 · NCT04830137

Study of SGR-1505 in Mature B-Cell Neoplasms

  • University of Texas Southwestern, Dallas
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT05544019

Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery

  • University of Texas Medical Branch at Galveston, TX, Galveston
Menerima peserta
Usia 50 ke atas · Wanita · Diperbarui 11 Feb 2026 · NCT07206121

Cognitive Screening Made Easy for PCPs - Administrative Supplement

  • Family Wellness Clinic, Austin
  • University of Texas Health Austin Primary Care Clinic, Austin
  • UT Health San Antonio's Geriatrics and Supportive Care Clinic, San Antonio
Menerima pesertaSukarelawan sehat diterima
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 5 Feb 2026 · NCT06928298

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • Oncology Consultants, Houston
  • University of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Des 2025 · NCT05602363

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

  • SCRI, San Antonio
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Nov 2025 · NCT05643742

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Dallas
  • Massive Bio SYNERGY-AI site, Houston
  • Massive Bio SYNERGY-AI site, Temple
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

  • University of Texas Southwestern Medical Center, Dallas
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2025 · NCT05780034

Phosphatidylethanol and Other Ethanol Consumption Markers

  • University of North Texas, Denton
  • University of Texas Health Science Center San Antonio, San Antonio
Menerima pesertaSukarelawan sehat diterima
Usia 21 ke atas · Semua jenis kelamin · Diperbarui 13 Mei 2025 · NCT06747364

Paper-Based and Smartphone-Based Memory Supports

  • UT Health Austin Comprehensive Memory Center, Austin
  • Baylor Scott & White Healthcare, Temple
  • Baylor University, Waco
Menerima peserta
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2024 · NCT06444841

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.